IOLCP IOL Chemicals and Pharmaceuticals Q1 FY26 results (Apr–Jun 2025) and concall
IOL Chemicals reported a strong start to FY26 with robust revenue and profit growth, driven by efficient execution and margin expansion. The company is progressing on strategic initiatives like API portfolio diversification, capacity expansion, and regulatory approvals, despite facing subdued pricing in certain chemical products and increased raw material costs. Management remains optimistic about achieving its full-year targets.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 |
|---|---|---|---|---|
| Revenue | 526 | 523 | 528 | 552 |
| EBITDA | 42 | 47 | 63 | 62 |
| Net profit | 19 | 21 | 32 | 34 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
